Lipigon Pharmaceuticals AB (FRA:9RP) EBITDA Margin %: 0.00% (As of Dec. 2025)


What is Lipigon Pharmaceuticals AB EBITDA Margin %?

Lipigon Pharmaceuticals AB FRA:9RP EBITDA Margin % is 0.00% as of Dec. 2025. The stock has 2 warning signs investors should review. Among 937 Biotechnology companies, Lipigon Pharmaceuticals AB ranks worse than 106723.48% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lipigon Pharmaceuticals AB's EBITDA for the three months ended in Dec. 2025 was €-0.66 Mil. Lipigon Pharmaceuticals AB's Revenue for the three months ended in Dec. 2025 was €0.00 Mil. Therefore, Lipigon Pharmaceuticals AB's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Lipigon Pharmaceuticals AB  (FRA:9RP) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Lipigon Pharmaceuticals AB EBITDA Margin % Related Terms

Lipigon Pharmaceuticals AB EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Lipigon Pharmaceuticals AB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipigon Pharmaceuticals AB EBITDA Margin % Chart

Lipigon Pharmaceuticals AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial -1,290.32 0.00 -73.76 -244.52 0.00

Lipigon Pharmaceuticals AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -806.09 0.00 0.00 0.00 0.00

FRA:9RP vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Lipigon Pharmaceuticals AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lipigon Pharmaceuticals AB EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipigon Pharmaceuticals AB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Lipigon Pharmaceuticals AB's EBITDA Margin % falls into.


Lipigon Pharmaceuticals AB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Lipigon Pharmaceuticals AB's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-2.943/0
= %

Lipigon Pharmaceuticals AB's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.662/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Lipigon Pharmaceuticals AB (FRA:9RP) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lipigon Pharmaceuticals AB and its competitors. According to the industry distribution chart, Lipigon Pharmaceuticals AB ranks #999999 out of 937 companies in the Biotechnology industry.
Is Lipigon Pharmaceuticals AB's EBITDA Margin % too high?
Lipigon Pharmaceuticals AB's current EBITDA Margin % is 0.00%. Based on the distribution chart, Lipigon Pharmaceuticals AB ranks #999999 out of 937 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Lipigon Pharmaceuticals AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lipigon Pharmaceuticals AB ranks #999999 out of 937 companies for EBITDA Margin %. This places Lipigon Pharmaceuticals AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lipigon Pharmaceuticals AB and its competitors. Lipigon Pharmaceuticals AB's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipigon Pharmaceuticals AB stock overvalued right now?
Lipigon Pharmaceuticals AB (FRA:9RP) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Lipigon Pharmaceuticals AB (FRA:9RP), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lipigon Pharmaceuticals AB Business Description

Address Tvistevagen 48 C, Umea, SWE, 90736
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.